Table 2 –
COVID-19 characteristics in COVID-19 cases (A+C) and (C+) controls
| A+C Cases | C+ Controls | P-value | |
|---|---|---|---|
| Initial presentation: - ED or urgent care - Primary care or telemedicine - Other/unknown |
19 (13.4%) 122 (85.9%) 1 (0.7%) |
113 (10.2%) 974 (87.8%) 23 (2.1%) |
0.58 |
| Recent travel | 10 (7.0%) | 34 (3.1%) | 0.009 |
| Known exposure | 86 (62.3%) | 746 (68.3%) | 0.16 |
| Interval, days: - Symptoms to presentation - Symptoms to test |
2 [1-3] 2.5 [1-4] |
2 [1-3] 2 [1-4] |
0.37 0.47 |
| Initial symptoms: - Asymptomatic - Fever - Fatigue - Cough - Wheezing - Dyspnea - Chest pain - Loss of smell - Loss of taste - Abdominal pain - Vomiting |
16 (11.3%) 53 (37.3%) 24 (16.9%) 62 (43.7%) 7 (4.9%) 13 (9.2%) 7 (4.9%) 23 (16.2%) 26 (18.3%) 8 (5.6%) 6 (4.2%) |
124 (11.2%) 443 (39.9%) 162 (14.6%) 477 (43.0%) 5 (0.5%) 25 (2.3%) 16 (1.4%) 125 (11.3%) 129 (11.6%) 52 (4.7%) 36 (3.2%) |
0.97 0.55 0.47 0.88 <0.001 <0.001 0.004 0.09 0.02 0.62 0.54 |
| Initial treatment: - Any pharmacologic treatment - Albuterol - Systemic steroids |
10 (7%) 25 (17.6%) 12 (8.5%) |
15 (1.3%) 8 (0.7%) 9 (0.8%) |
<0.001 <0.001 <0.001 |
| Main outcomes | |||
| Hospitalized | 7 (4.9%) | 19 (1.7%) | 0.01 |
| Hospital LOS (days) | 1 [1-4] | 2 [1-4] | 0.51 |
| Respiratory support1: - None (room air) - Nasal cannula (NC) - High-flow NC or NPAP - Invasive ventilation |
6 0 1 0 |
14 2 2 1 |
0.72 |
Numbers represent mean (SD) or median [interquartile range] for continuous variables, and n (%) for categorical variables.
1
Among hospitalized patients.
LOS: Length of stay (days).